Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer

NCT01196559 ↗

Phase 2 Completed 44 enrolled The Catholic University of Korea Korean Cancer Study Group · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the objective response rate and safety in platinum-resistant epithelial ovarian/fallopian tube/primary peritoneal cancer patients treated with vinorelbine and gemcitabine combination chemotherapy.

Timeline

Start: 2011-01
Primary completion: 2014-10
Completion: 2014-10

Outcome

Met primary endpoint

paper The combination chemotherapy with gemcitabine and vinorelbine achieved the primary end point of our clinical trial PMID 25462205 ↗

Publications

Hong SH, Lee S, Kim HG, Lee HJ, Jung KH, Lee SC, Lee NR, Yun J, Woo IS, Park KH, Kim KH, Kim HY, Rha SY, Byun JH. Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10. Gynecol Oncol. 2015 Feb;136(2):212-7. doi: 10.1016/j.ygyno.2014.11.017. Epub 2014 Nov 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Subject	Vinorelbine	Small molecule	25 mg/m2	Intravenous